Today's Trend
Sabra Healthcare REIT, Inc. (NASDAQ: SBRA) has been moving higher after a string of upbeat business and analyst updates. The most important catalysts were Sabra’s raised full-year 2026 guidance and a portfolio reshaping plan that could improve operations and cash flow, which investors tend to view favorably for a healthcare REIT.
- Truist Financial raised its price target on Sabra Healthcare REIT from $22 to $24 and reiterated a buy rating, signaling confidence in further upside. Benzinga
- Citizens JMP lifted its price target from $23 to $25 and maintained a market outperform rating, suggesting analysts see additional room for the stock to climb. Benzinga
- Sabra increased FY 2026 EPS guidance to $1.53-$1.55, above the consensus estimate of $1.50, which supports the case for stronger-than-expected earnings. Business Wire
- The company announced a major portfolio reshaping, including plans to re-tenant properties previously leased to Avamere, which may improve occupancy stability and operational quality over time. TipRanks
- Zacks noted SBRA was a strong recent mover on heavy volume, but also warned that recent FFO estimate revisions could limit near-term follow-through. Zacks
Overall, SBRA appears to be benefiting from improved guidance, strategic portfolio changes, and multiple analyst target hikes, which helps explain why the stock has been trading stronger lately.